Gilead third-quarter results in line, but Yescarta sales dip

Gilead Sciences Inc on Thursday posted third-quarter results largely in line with Wall Street estimates, led by higher HIV drug sales, but sales of cancer cell therapy Yescarta fell slightly from the previous quarter.